Shares of Illumina Inc. jumped more than 13% in the extended session Monday after the biotech company said it expects first-quarter revenue to top $1 billion thanks to “record” orders and revenue growth in its gene-sequencing and related businesses. Illumina said it expects first-quarter revenue of about $1.085 billion, which would compare with revenue of $859 million in the first quarter of 2020. For fiscal 2021, Illumina said it now expects year-over-year revenue growth in a range between 25% and 28% compared with fiscal 2020. The revenue growth demonstrates “the solid recovery from the COVID-19 pandemic and the strength of our core business. Most customers are now at or above pre-COVID activity levels,” Illumina said in a statement. Illumina shares ended the regular trading day down 0.1%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.